Aastrom to Present at the 13th Annual Rodman & Renshaw Healthcare Conference
08 September 2011 - 11:00PM
Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of
patient-specific, expanded multicellular therapies for the
treatment of severe, chronic cardiovascular diseases, today
announced that company president and CEO Tim Mayleben will speak at
the 13th Annual Rodman & Renshaw Healthcare Conference, which
is being held September 11-13, 2011, at the Waldorf Astoria in New
York City.
The Aastrom presentation will take place from 9:35 A.M. to 10:00
A.M. (EDT) on September 12, 2011. The presentation will be webcast
live and will also be accessible in archive until December 11,
2011, beginning one hour after the presentation. The URL for live
and archived access to the presentation is
http://www.wsw.com/webcast/rrshq20/astm. Participants should allow
approximately five to ten minutes prior to the presentation start
time to visit the site and download any streaming media software
needed to listen to the webcast.
About Aastrom Biosciences
Aastrom Biosciences is developing patient-specific, expanded
multicellular therapies for use in the treatment of severe, chronic
cardiovascular diseases. The company's proprietary
cell-processing technology enables the manufacture of ixmyelocel-T,
a patient-specific multicellular therapy expanded from a patient's
own bone marrow and delivered directly to damaged tissues. Aastrom
has advanced ixmyelocel-T into late-stage clinical development,
including a planned Phase 3 clinical program to study patients with
critical limb ischemia and two Phase 2 clinical trials in patients
with dilated cardiomyopathy. For more information, please visit
Aastrom's website at www.aastrom.com.
The Aastrom Biosciences, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=3663
This document contains forward-looking statements, including,
without limitation, statements concerning clinical trial plans and
progress, objectives and expectations, clinical activity timing,
intended product development, the performance and contribution of
certain individuals and expected timing of collecting and analyzing
treatment data, all of which involve certain risks and
uncertainties. These statements are often, but are not always, made
through the use of words or phrases such as "anticipates,"
"intends," "estimates," "plans," "expects," "we believe," "we
intend," and similar words or phrases, or future or conditional
verbs such as "will," "would," "should," "potential," "could,"
"may," or similar expressions. Actual results may differ
significantly from the expectations contained in the
forward-looking statements. Among the factors that may result in
differences are the inherent uncertainties associated with clinical
trial and product development activities, regulatory approval
requirements, competitive developments, and the availability of
resources and the allocation of resources among different potential
uses. These and other significant factors are discussed in greater
detail in Aastrom's Annual or Transition Report on Form 10-K or
10-K/T, Quarterly Reports on Form 10-Q and other filings with the
Securities and Exchange Commission. These forward-looking
statements reflect management's current views and Aastrom does not
undertake to update any of these forward-looking statements to
reflect a change in its views or events or circumstances that occur
after the date of this release except as required by law.
CONTACT: Media contact
Bill Berry
Berry & Company
bberry@berrypr.com
(212) 253-8881
Investor contact
Danielle Spangler
The Trout Group
dspangler@troutgroup.com
(646) 378-2924
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Sep 2023 to Sep 2024